Changes in hemoglobin levels and cardiometabolic health in adults with metabolic syndrome - a secondary outcome analysis of a six-month randomized controlled trial.
Jasmina Gassner, Jooa Norha, Tanja Sjöros et al.
✦ AI-curated · Sources linked
In 30 seconds
This secondary outcome analysis of a six-month randomized controlled trial examined whether hemoglobin (Hb) changes tracked cardiometabolic changes in 64 adults with metabolic syndrome participating in a sedentary-behavior intervention. The intervention did not significantly change Hb, and Hb changes were not consistently associated with cardiometabolic changes. However, lower Hb was associated with lower fasting glucose (r = 0.29, p = 0.032), improved insulin sensitivity (r = -0.26, p = 0.045), and increased cardiorespiratory fitness (r = -0.29, p = 0.033). These correlations do not establish that Hb changes caused the improvements.
Key findings
- The intervention did not significantly affect Hb levels, and Hb changes did not correlate with most cardiometabolic changes.
- Reduced Hb correlated with reduced fasting blood glucose (r = 0.29, p = 0.032).
- Reduced Hb correlated with improved insulin sensitivity (r = -0.26, p = 0.045) and increased cardiorespiratory fitness (r = -0.29, p = 0.033).
- At baseline and across measurements, higher Hb was associated with lower insulin sensitivity (r = -0.35, p = 0.005) and higher liver fat content (r = 0.40, p = 0.011).
Why it matters
The findings suggest that Hb may track some metabolic and fitness measures in adults with metabolic syndrome, but the associations during intervention were limited and inconsistent. This distinction matters when interpreting Hb as a cardiometabolic marker: observed correlations do not show that changing Hb improves metabolic health. The results support further investigation rather than a causal interpretation.
What to keep in mind
This was a secondary analysis of a six-month intervention trial, and the reported Hb-change findings are correlations; they cannot establish causality.